FAB Passes FDA Inspection with Zero Deficiencies,Accelerating FDA Approval of Nuvation Bio’s Taletrectinib
On June 11, 2025, Nuvation Bio (parent company of AnHeart Therapeutics) announced that U.S. Food and Drug Administration (FDA) approved its drugTaletrectinib Adipate Capsules(herea...